New England Journal of Medicine news from FierceBiotech
News
ALSO NOTED: Dyax to close R&D facility;Nastech sells shares; and much more...
> Dyax says it plans to close its research facility in Belgium as it focuses on commercializing DX-88 to treat hereditary angioedema. Read more...
Cardiome's CBO discusses changes at FDA
During a conference call with investors yesterday, Cardiome's President and Chief Business Officer, Doug Janzen, had some interesting thoughts on the Read more...
ALSO NOTED: CFOs are pharma's new power players; Progen axes staff in restructuring; MethylGene inks collaboration deal;and muc
> Australia's Progen is laying off workers in a restructuring that includes outsourcing the commercial manufacture of PI-88. Read more...
Theratechnologies explores sale, other options
Theratechnologies has posted a "sale" sign on the company as it announced its intention to conduct a strategic review of its options. At the same time, the Canadian developer said that it is Read more...
Studies inflating antidepressant efficacy?
Yesterday we reported on an article published in the New England Journal of Medicine that found studies with Read more...
Positive data more likely to find its way to public
There's been a growing understanding in the drug development world that studies boasting of positive data on a drug tend to get published in the scientific literature with great fanfare; negative Read more...
Researcher calls FDA 'shortcuts' into question
A high-profile researcher has issued what is now one of many public challenges to the manner in which the FDA speeds approval of certain drugs. Researcher Dr. Clifford J. Rosen is concerned, in Read more...
What to do with Avandia sales force?
GlaxoSmithKline may cut or redeploy its Avandia sales force in the wake of safety concerns that have virtually destroyed the drugs sales. Avandia is GSK’s second bestselling drug, earning £1.4 Read more...
Press Release: GlaxoSmithKline Receives Approvable Letter For New Indications For ARIXTRA
Press Release: GlaxoSmithKline Receives Approvable Letter For New Indications For ARIXTRA
Read more...Press Release: Aastrom Receives Orphan Drug Designation from FDA for Dilated Cardiomyopathy
Press Release: Aastrom Receives Orphan Drug Designation from FDA for Dilated Cardiomyopathy
Read more...Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends